Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) announced the nomination of Dr. Wolfgang Hofmann for election as an independent member of the Supervisory Board at the company’s upcoming Annual General Meeting (AGM) on June 11, 2026. The AGM agenda also includes the previously announced nomination of Dieter Weinand as Chairman of the Supervisory Board and a proposal to increase the board size from six to seven members.
Following constructive discussions, Evotec has entered into a cooperation agreement with MAK Capital Fund LP, a key shareholder. Under the terms, MAK Capital has agreed to customary voting and cooperation commitments. This agreement reflects Evotec’s commitment to open shareholder dialogue and supports long-term value creation.
Prof. Dr. Iris Low-Friedrich, Chairwoman of Evotec’s Supervisory Board, stated: “We are pleased to nominate Wolfgang for election at the upcoming AGM. His appointment would contribute oversight and governance capabilities through additional industry, scientific and governance expertise, complementing our existing Board structure as we continue to implement our transformation plans to grow shareholder value.”
Michael A. Kaufman, Chief Executive Officer of MAK Capital, said: “We appreciate the constructive dialogue and welcome Wolfgang’s nomination to the Supervisory Board. We look forward to continuing our collaboration with the Supervisory Board and Management Board to support Evotec's ongoing transformation.”
Evotec is a life science company pioneering drug discovery and development, integrating breakthrough science with AI-driven innovation. The company’s expertise spans small molecules, biologics, cell therapies, and more, supported by proprietary platforms. With over 4,500 experts, Evotec works with top pharmaceutical companies and biotechs. The nomination and cooperation agreement underscore Evotec’s focus on enhancing governance as it executes its transformation strategy. For more information, visit www.evotec.com.
